Curated News
By: NewsRamp Editorial Staff
October 30, 2026
VERAXA Biotech Expands Human-Relevant Testing for Cancer Drugs
TLDR
- VERAXA Biotech expands human-relevant NAMs across antibody programs, gaining a preclinical edge by cutting animal use while boosting clinical relevance.
- VERAXA uses 3D tumor spheroids and patient-derived models to test BiTAC T-cell engagers, ADCs and bispecific ADCs, cutting mouse use from 200 to about 10.
- VERAXA's shift to human-relevant testing reduces animal reliance and may speed safer, more effective cancer therapies to patients.
- VERAXA's lead BiTAC T-cell engager killed tumor cells across 10 patient-derived lung cancer models with minimal control activity.
Impact - Why it Matters
This news matters because it signals a potential shift in how preclinical cancer research is conducted, prioritizing human-relevant models over traditional animal testing. By adopting NAMs, VERAXA Biotech (NASDAQ: VRXA) aims to improve the predictive validity of its antibody-based therapeutics, which could lead to faster and more reliable translation of promising drug candidates into clinical trials. The company's lead BiTAC T-cell engager showed potent activity across multiple patient-derived tumor models while using significantly fewer mice, addressing both ethical and efficiency concerns. If successful, this approach could set a new standard for preclinical testing in oncology, ultimately accelerating the development of safer and more effective treatments for patients. For investors, it highlights VERAXA's commitment to innovation and its potential to streamline drug development, potentially reducing costs and time to market.
Summary
VERAXA Biotech (NASDAQ: VRXA) is expanding its use of human-relevant preclinical testing methods across its antibody-based cancer drug development programs, aiming to improve the clinical relevance of research findings while reducing animal testing. The company is implementing New Approach Methodologies (NAMs), including three-dimensional tumor spheroid models and patient-derived tumor models, in support of its BiTAC® T-cell engagers, antibody-drug conjugates (ADCs) and bispecific antibody-drug conjugates. VERAXA reported that its lead BiTAC T-cell engager demonstrated selective, potent T-cell-mediated tumor-cell killing across 10 patient-derived non-small cell lung cancer models, while relevant controls showed minimal activity. The ex vivo study required approximately 10 mice, compared with an estimated 200 or more for comparable in vivo efficacy studies, according to the company. The findings support VERAXA’s dual-targeting approach, which is designed to direct immune activity toward cancer cells expressing two selected targets, and its broader strategy of using human-relevant models in preclinical research.
To view the full article, visit https://ibn.fm/jZrd2
VERAXA Biotech AG is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technology. For regular updates about VERAXA Biotech, visit https://investors.veraxa.com.
The announcement was distributed through InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio @ IBN, which offers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution and tailored corporate communications solutions. For more information, visit https://www.InvestorWire.com.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, VERAXA Biotech Expands Human-Relevant Testing for Cancer Drugs
